Ionis Pharmaceuticals to present at 38th annual J.P. Morgan Healthcare ConferenceHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Ionis Pharmaceuticals to present at 38th annual J.P. Morgan Healthcare ConferencePR NewswireJanuary 6, 2020ReblogShareTweetShareCARLSBAD, Calif., Jan. 6, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 38th annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2020 at 7:30 a.m. PT in San Francisco, CA.(PRNewsfoto/Ionis Pharmaceuticals, Inc.)MoreThe above listed date and time are subject to change. For the latest information, please visit www.ionispharma.com.A live webcast of the presentation will be available on the Investors & Media section of the Ionis website. The replay will be available within 48 hours and archived for a limited time.ABOUT IONIS PHARMACEUTICALS, INC.As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 novel medicines designed to treat a broad range of diseases including cardiovascular diseases, neurological diseases, infectious diseases, pulmonary diseases and cancer.To learn more about Ionis visit www.ionispharma.com and follow us on twitter @ionispharma. CisionMoreView original content to download multimedia:http://www.prnewswire.com/news-releases/ionis-pharmaceuticals-to-present-at-38th-annual-jp-morgan-healthcare-conference-300981094.htmlSOURCE Ionis Pharmaceuticals, Inc.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextBaidu Becomes Latest Tech Giant to Deliver Disappointing OutlookBloombergRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoKorea Cases Top 2,000; Nigeria Confirms Infection: Virus UpdateBloombergStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoNigeria confirms coronavirus case, first in sub-Saharan AfricaAFPStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo Finance'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceSomething 'dangerous' is happening beneath the surface of the market selloffYahoo Finance